- Report Scope:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies
- Get an understanding of trends shaping and driving the global T2D market
- Understand innovative products and technologies, market segments, and companies likely to impact the global T2D market in future
- Analyze performance of competitors in the T2D space
The T2D pipeline features 551 products across all stages of clinical development, with non-‘me-too’ drugs prominently featured in early-stage clinical trials. Metabolic diseases R&D efforts are focused on T2D, with 7,840 clinical trials (based on clinical trials initiated from 1995 to now).
T2D clinical trials focus on cardiovascular outcomes, with 24.4% of clinical trials in ongoing status, however only 3% of clinical trials are planned for initiation. New drug approvals are expected to drive T2D market growth over the next decade.
GlobalData’s Biosimilars market report provides in-house analyst expertise and a competitive assessment of the disease market. This report will allow you to assess the pipeline, clinical, and commercial landscape of T2D.